Effectiveness of Electroacupuncture Combined with Pregabalin in the Treatment of Trigeminal Herpetic Neuralgia: A Multicenter Randomized Controlled Trial Study Protocol
Authors:
- Shimin LiSLShimin Li
- Xilong YangXYXilong Yang
- Yunfan XiaYXYunfan Xia
- Yunyan ShenYSYunyan Shen
- Jingfang LiJLJingfang Li
- Chengcheng KongCKChengcheng Kong
- Hui WangHWHui Wang
- Ruohan SunRSRuohan Sun
- Zhiyuan BianZBZhiyuan Bian
- Zuyong ZhangZZZuyong Zhang
- Jianqiao FangJFJianqiao Fang
- Ping LinPLPing Lin
- 31 October 2025
- journal article
- Published by S. Karger AG in Complementary Medicine Research
- Vol. 32 (6) , 485-494
Abstract
Background: Trigeminal herpetic neuralgia, a common type of Zoster-associated pain (ZAP), affects individuals across all ages groups and poses a significant societal burden all over the world. Electroacupuncture (EA) is increasingly used in the treatment of ZAP due to its affordability, high safety profile, absence of adverse reactions, and high patient acceptance. Consequently, it is essential to conduct randomized controlled trials to evaluate the effectiveness and safety of EA in treating ZAP and to determine if EA can be used as an alternative to pregabalin. Patients and Methods: A total of 102 patients with trigeminal herpetic neuralgia will be enrolled from 2 hospitals and randomly assigned to the EA group, pregabalin group, or EA + pregabalin group in a 1:1:1 ratio using a simple random number table. The study will consist of a 4-week treatment period followed by a 4-week follow-up period. The primary outcome measure will be pain intensity, while secondary outcomes will include mood state, sleep quality, and quality of life. Adverse reactions will be thoroughly evaluated. Conclusion: This study aims to elucidate the clinical effectiveness of EA combined with pregabalin for trigeminal herpetic neuralgia and to objectively compare the effectiveness and safety of EA versus oral pregabalin in the treatment of trigeminal herpetic neuralgia.Keywords
This publication has 18 references indexed in Scilit:
- Pregabalin inhibits purinergic P2Y2 receptor and TRPV4 to suppress astrocyte activation and to relieve neuropathic painEuropean Journal of Pharmacology, 2023
- Pregabalin alleviates neuropathic pain via inhibition of the PKCε/TRPV1 pathwayNeuroscience Letters, 2022
- Neuropathic Corneal PainOphthalmology, 2017
- Acupuncture for the Treatment of Peripheral Neuropathy: A Systematic Review and Meta-AnalysisThe Journal of Alternative and Complementary Medicine, 2017
- Endogenous analgesic effect of pregabalin: A double-blind and randomized controlled trialEuropean journal of pain, 2017
- Postherpetic NeuralgiaNew England Journal of Medicine, 2014
- Interventional management of neuropathic pain: NeuPSIG recommendationsPain, 2013
- Management of Herpes Zoster and Post-Herpetic NeuralgiaAmerican Journal of Clinical Dermatology, 2013
- Pain, Medication Use, and Health-Related Quality of Life in Older Persons With Postherpetic Neuralgia: Results From a Population-Based SurveyThe Journal of Pain, 2005
- Effect of low- and high-frequency TENS on Met-enkephalin-Arg-Phe and dynorphin A immunoreactivity in human lumbar CSFPain, 1991